Financials' strength keeps ISEQ up

Warner Chilcott's FDA approval for menopause symptom drug Femtrace has not helped the company share price this morning, after it fell by nine cent to €8.87.

Financials' strength keeps ISEQ up

Warner Chilcott's FDA approval for menopause symptom drug Femtrace has not helped the company share price this morning, after it fell by nine cent to €8.87.

The company expects to launch Femtrace tablets in the first quarter of 2005.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited